AL Amyloidosis and Anti-CD38-Daratunumab
NCT06571864
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
14
Enrollment
OTHER
Sponsor class
Conditions
Amyloidosis
Interventions
DRUG:
Anti-CD38 Monoclonal Antibody
Sponsor
University of Turin, Italy